Renaissance Technologies LLC Boosts Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Renaissance Technologies LLC lifted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 29.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 6,951,152 shares of the company's stock after purchasing an additional 1,562,302 shares during the period. Renaissance Technologies LLC owned about 3.18% of Hims & Hers Health worth $168,079,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after acquiring an additional 4,145,305 shares during the period. State Street Corp raised its position in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock worth $85,221,000 after acquiring an additional 206,078 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after purchasing an additional 40,447 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after purchasing an additional 883,230 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts have commented on HIMS shares. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Piper Sandler increased their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, February 25th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Leerink Partners upped their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Finally, BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price objective for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $38.25.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $24.44, for a total value of $283,039.64. Following the completion of the transaction, the chief financial officer now directly owns 118,077 shares in the company, valued at $2,885,801.88. The trade was a 8.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at $756,298.62. This trade represents a 56.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 835,884 shares of company stock valued at $31,659,701. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Trading Up 1.2 %

Shares of HIMS stock traded up $0.32 during mid-day trading on Friday, reaching $27.13. The stock had a trading volume of 16,210,541 shares, compared to its average volume of 15,146,132. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The firm has a market cap of $6.03 billion, a price-to-earnings ratio of 61.66 and a beta of 1.65. The business's fifty day moving average is $38.75 and its 200-day moving average is $30.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.